473299-49-9Relevant articles and documents
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes
Liu, Ping,Hu, Zhiyong,Dubois, Byron G.,Moyes, Christopher R.,Hunter, David N.,Zhu, Cheng,Kar, Nam Fung,Zhu, Yuping,Garfunkle, Joie,Kang, Ling,Chicchi, Gary,Ehrhardt, Anka,Woods, Andrea,Seo, Toru,Woods, Morgan,Van Heek, Margaret,Dingley, Karen H.,Pang, Jianmei,Salituro, Gino M.,Powell, Joyce,Terebetski, Jenna L.,Hornak, Viktor,Campeau, Louis-Charles,Lamberson, Joe,Ujjainwalla, Fez,Miller, Michael,Stamford, Andrew,Wood, Harold B.,Kowalski, Timothy,Nargund, Ravi P.,Edmondson, Scott D.
supporting information, p. 936 - 941 (2015/08/24)
We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analo
SUBSTITUTED CYCLOPROPYL COMPOUNDS
-
Page/Page column 49, (2014/04/17)
Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.
SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT
-
Page/Page column 52-53, (2013/02/28)
Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled rece
GPCR AGONISTS
-
Page/Page column 27, (2010/11/25)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
-
, (2008/06/13)
Methods of treating cyclooxygenase-2 mediated disorders comprising administering to a subject a therapeutically effective amount of one or more fluoro-substituted benzenesulfonyl compounds corresponding to Formula I: wherein A, X, n, R1, R